Ypsomed Holding AG
YPSN
ISIN CH0019396990 / Valor 1939699
Ypsomed Holding AG
UMushroom community rating:
About company
Ypsomed Holding AG is a Swiss company specializing in the development and production of injection and infusion systems for self-medication, primarily serving the pharmaceutical and biotechnology sectors. The company operates through two main divisions: Ypsomed Delivery Systems (YDS) and mylife Diabetescare. YDS provides a wide array of technologies and services designed to ensure reliable and user-friendly injection systems, catering to companies that develop and market injectable therapies. Meanwhile, the mylife Diabetescare brand offers a comprehensive range of products and services aimed at simplifying self-treatment for individuals with diabetes, enhancing their ability to manage their condition discreetly and effectively. Ypsomed's focus on innovation and user-centric design positions it as a key player in the medical technology industry, particularly in the field of self-administered drug delivery solutions.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (01.10.2025):
Ypsomed Holding AG reported strong financial performance for the full year 2024/25, demonstrating significant revenue growth and strategic advancements in their delivery systems segment.
Revenue Growth
Delivery Systems generated CHF 501 million in revenue for the fiscal year 2024/25, reflecting a robust 30% increase compared to the previous year.
Sales Expansion
The company achieved above-average sales growth of 150% for commercial autoinjectors, supported by the acquisition of 36 new projects across various platforms and customer segments.
Strategic Transformation
Ypsomed transitioned into a focused pure-play injection systems specialist by divesting non-core businesses, including the sale of DiaExpert retail business and pen needle segments, thereby enhancing its market position.
Capacity Enhancement
Significant capacity additions were made in 2024/25, with 120 million units per year of additional assembly capacity and the qualification of four new assembly lines and 38 injection molding machines, aiming for a total disposable unit capacity of approximately 300 million per year.
Project and Client Diversification
Ypsomed is actively engaged in over 230 projects with 130 diverse clients, broadening its product portfolio to cover multiple disease areas and ensuring a well-diversified revenue stream.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
5592 M
Market cap (USD)
16,779
Daily traded volume (Shares)
340 / 328
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Khiem Tran
Khiem Tran
EQUITIES OF THE SAME SECTOR
